"Michigan Vascular Center specializes in medical and surgical treatment of vascular diseases. We work with all three hospitals in Genesee County and have five offices giving patients the opportunity to be cared for in a timely fashion. Having over fifty years of experience and a group of healthcare providers provides patients with comprehensive care."

During the past decade, Michigan Vascular Center conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 9 clinical trials were completed, i.e. on average, 64.3% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 5 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Michigan Vascular Center" #1 sponsor was "Angiotech Pharmaceuticals" with 2 trials, followed by "Boston Scientific Corporation" with 2 trials sponsored, "C. R. Bard" with 2 trials sponsored, "Humacyte, Inc." with 2 trials sponsored and "Medtronic Cardiovascular" with 2 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Michigan Vascular Center" #1 collaborator was "Massachusetts General Hospital" with 3 trials as a collaborator, "National Institute of Neurological Disorders and Stroke (NINDS)" with 2 trials as a collaborator, "University of Alabama at Birmingham" with 2 trials as a collaborator, "Abbott" with 1 trials as a collaborator and "Atlantic Research Group" with 1 trials as a collaborator. Other collaborators include 31 different institutions and companies that were collaborators in the rest 41 trials.

According to Clinical.Site data, the most researched conditions in "Michigan Vascular Center" are "Peripheral Arterial Disease" (5 trials), "Arteriovenous Fistula" (2 trials), "Carotid Artery Disease" (2 trials), "Carotid Stenosis" (2 trials) and "Critical Limb Ischemia" (2 trials). Many other conditions were trialed in "Michigan Vascular Center" in a lesser frequency.

Most popular intervention types in "Michigan Vascular Center" are "Device" (20 trials), "Procedure" (6 trials), "Biological" (4 trials), "Diagnostic Test" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Human Acellular Vessel (HAV)" (2 trials), "Ixmyelocel-T" (2 trials), "Placebo" (2 trials), "Anaconda ONE-LOK Stent Graft System" (1 trials) and "Anaconda Stent Graft System" (1 trials). Other intervention names were less common.

The vast majority of trials in "Michigan Vascular Center" are 28 trials for "All" genders.

Currently, there are NaN active trials in "Michigan Vascular Center". undefined are not yet recruiting, undefined are recruiting, 6 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 15 completed trials in Michigan Vascular Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Michigan Vascular Center, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 15 trials that are defined as “Not Applicable".